Ireland’s new obesity strategy — 6 critical facts to know.

Ireland’s new obesity strategy is being drafted right now, and one detail sets it apart from every obesity policy that came before it: for the first time, it must genuinely account for a class of medication effective enough to change national health outcomes at scale.

This guide explains why the old policy is being replaced, what internal government documents reveal about the thinking behind the new one, and what the public consultation uncovered. Official policy information is published by the Department of Health.

Ireland’s new obesity strategy — fact 1: why replacement is needed

Ireland’s current framework, A Healthy Weight for Ireland: Obesity Policy and Action Plan (OPAP), launched in September 2016 and was always designed to run a ten-year course through to the end of 2025. A successor policy was always going to be needed on schedule — but the world it needs to address has shifted dramatically since 2016.

The Department of Health has been explicit that the new strategy will build on OPAP’s foundations while addressing what it calls “new and emerging challenges” — language that, as the details below make clear, is substantially about the arrival of effective pharmacological treatment options that simply didn’t exist in their current form when the original policy was written.

Ireland’s new obesity strategy — fact 2: the GLP-1 factor

This is the most striking detail uncovered in reporting on the new strategy’s development. Minutes from meetings of the Obesity Policy Implementation Oversight Group in 2024 specifically noted the need for input from the HSE’s pharmacology unit regarding the next plan — attributed directly to the rise of Ozempic and other obesity drugs in recent years.

This is a genuinely significant shift in how Ireland’s obesity policy is being constructed. The 2016 OPAP was built almost entirely around prevention, education, and lifestyle intervention — a research report on the current state of Irish obesity care noted that despite obesity being recognised as a chronic disease, clinical management has remained largely limited to lifestyle advice, with pharmacological and surgical options still underutilised. The new strategy appears set to formally grapple with medication as a genuine, mainstream treatment pathway for the first time.

Ireland’s new obesity strategy — fact 3: the numbers

According to the Department of Health, approximately 56 to 60% of adults and roughly one in five children in Ireland currently live with overweight or obesity. The Minister has stated that the current policy has helped stabilise these rates compared to the sharp rises seen in earlier decades, though further reductions remain the explicit goal.

Ireland’s new obesity strategy — fact 4: what OPAP achieved

Before looking forward, it’s worth crediting what the outgoing policy actually delivered. Key achievements cited by the Department include the introduction of the Sugar-Sweetened Drinks Tax in 2018, with a 2024 evaluation showing genuinely reduced consumption of sugary beverages as a direct result.

Other cited achievements include healthy eating guidelines tailored specifically for young children and older adults, a national food reformulation roadmap with a dedicated implementation taskforce, and — most relevant to this website’s readers — the development of the HSE’s Model of Care for the Management of Overweight and Obesity, the clinical framework underpinning current specialist weight management services.

Despite these genuine achievements, the Department itself has acknowledged an uncomfortable reality alongside them: the HSE continues to record some of the highest obesity rates in Europe, even after a decade of dedicated policy effort. This tension — real progress on specific initiatives alongside persistently high overall rates — is precisely what the new strategy is being asked to address more directly.

Ireland’s new obesity strategy — the childhood obesity dimension

A significant and often under-discussed element of Ireland’s obesity strategy work concerns children specifically. Data from the Childhood Obesity Surveillance Initiative shows roughly one in five primary school children in Ireland currently live with overweight or obesity, a figure that has remained stubbornly consistent across recent survey years.

Research specifically examining child and adolescent obesity management in Ireland has identified genuine implementation gaps in clinical practice — surveying 184 healthcare professionals found that while the majority conduct routine growth monitoring, only around a third actually provide a formal diagnosis of paediatric obesity as part of standard care, pointing to real barriers in how the healthcare system currently identifies and addresses the issue in younger patients specifically.

Given that Ireland’s original OPAP placed particular emphasis on childhood obesity as a whole-of-government priority, it is reasonable to expect the new strategy will continue — and likely deepen — this focus, particularly given how much more effectively childhood obesity can potentially be addressed through early intervention compared to established adult obesity.

Ireland’s new obesity strategy — fact 5: the public consultation

The Department of Health launched a formal public consultation, led by Minister of State Jennifer Murnane O’Connor, inviting individuals, healthcare professionals, and organisations to submit their views on the objectives and approach for the new strategy. The consultation closed in September 2025, with all submissions compiled into a report guiding the final drafting process.

This kind of open consultation process reflects a genuine attempt to broaden input beyond government departments alone — earlier preparatory work included a dedicated workshop with government departments, public health bodies, advocacy groups, and academics specifically to identify key themes before the consultation was even opened.

Ireland’s new obesity strategy — fact 6: the realistic timeline

The Department of Health had targeted early 2026 for publication of the new strategy, based on parliamentary statements made during preparatory stages. As with many government policy timelines, this date should be treated as a target rather than a guarantee, particularly given the added complexity of properly addressing pharmacological treatment for the first time.

This new obesity strategy will sit alongside, and likely reference, the separate but closely related HSE decision on Mounjaro reimbursement, which we cover in detail in our dedicated update. Both processes are moving broadly in parallel, and together they represent the most significant shift in Ireland’s approach to obesity in a decade.

For more on the related medication funding question, read our guide on is Mounjaro covered by the HSE. Explore our Mounjaro product page, or read patient reviews.

Whatever form the final published strategy takes, its arrival marks a meaningful moment for anyone following weight management policy in Ireland — the first comprehensive national framework written in an era where effective medication is genuinely part of the conversation, not an afterthought.

We will continue monitoring developments on both the new obesity strategy and the parallel Mounjaro reimbursement decision, updating our guides as further details are confirmed by the Department of Health and the HSE throughout the remainder of 2026.